...
机译:Alisentib的II期临床试验,Aurora激酶抑制剂,与急性髓性白血病的高风险,未处理患者的诱导化疗组合
Harvard Med Sch Massachusetts Gen Hosp Ctr Canc Boston MA USA;
Dana Farber Canc Inst Dept Biostat &
Computat Biol Boston MA 02115 USA;
Dana Farber Canc Inst Boston MA 02115 USA;
Harvard Med Sch Beth Israel Deaconess Med Ctr Boston MA USA;
Dana Farber Canc Inst Boston MA 02115 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Dana Farber Canc Inst Boston MA 02115 USA;
Dana Farber Canc Inst Boston MA 02115 USA;
Dana Farber Canc Inst Boston MA 02115 USA;
Dana Farber Canc Inst Boston MA 02115 USA;
Univ Virginia Hlth Syst Div Hematol Oncol Charlottesville VA USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Hematol Oncol Boston MA 02114 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Dana Farber Canc Inst Boston MA 02115 USA;
Harvard Med Sch Beth Israel Deaconess Med Ctr Boston MA USA;
Massachusetts Gen Hosp Ctr Canc Boston MA USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Dana Farber Canc Inst Dept Biostat &
Computat Biol Boston MA 02115 USA;
Massachusetts Gen Hosp Boston MA 02114 USA;
Massachusetts Gen Hosp Ctr Canc Boston MA USA;
Harvard Med Sch Massachusetts Gen Hosp Ctr Canc Boston MA USA;
机译:Alisentib的II期临床试验,Aurora激酶抑制剂,与急性髓性白血病的高风险,未处理患者的诱导化疗组合
机译:Clofarabine与预先治疗的中间体和坏风险急性髓性白血病(AML)或高风险骨髓增生综合征(HR-MDS)的患者中的标准缓解诱导方案(胞嘧啶阿拉伯苷和含替代素)组合的患者:持续阶段的阶段 E / II研究EORTC和GIMEMA的白血病组(EORTC Gimema 06061 / AML-14A试验)。
机译:结论:对于≥60岁的急性髓细胞性白血病患者,单独或与组蛋白脱乙酰酶抑制剂丙戊酸(VPA)和全反式维甲酸(ATRA)联合应用低剂量地西他滨(DAC)的前瞻性随机多中心II期临床研究不适合进行诱导化疗的人
机译:重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
机译:ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
机译:Aurora A激酶抑制剂alisertib的I期研究急性髓性白血病患者的诱导化疗
机译:I阶段研究Aurora激酶抑制剂Alisentib与急性髓细胞白血病患者的诱导化疗